Pair page — what's published on the two together
Pramlintide with Semaglutide
Studied together only in case reports: adults with type 1 diabetes and obesity, and a child with a rare genetic obesity syndrome.
The receipt
2 studies gave them to people together
Human pilots · Case reports (2023, 2026)
- Evidence on the combination
- Human pilots
Wong et al., 2023 · Stewart et al., 2026
What each does alone
- Weight loss · Daily shotPramlintideAmylinApproved in 2005 for diabetics on insulin: three shots a day, boxed warning. Not a weight-loss drug.Controlled trialsFDA approvedfor another useChecked Oct 23
- Weight loss · Weekly shotSemaglutideGLP-1The weekly shot the FDA approved as Ozempic and Wegovy. Weight loss in its main trial: 14.9%, on average.Approved drugFDA approvedChecked Oct 18
Mechanism overlap · reasoning, not evidence
- Pramlintide
- Peptide — Synthetic Amylin Analog
- Semaglutide
- GLP-1 Receptor Agonist — Metabolic
Reasoning, not evidence: what each is described to do says nothing about what they do together.
What the studies found
Type 1 diabetes with obesity (Wong et al., 2023)
- What was given — 3 patients prescribed a GLP-1 drug plus pramlintide; 2 of them took semaglutide.
- What it found — One lost 20.9 kg (16.1%) over 10 months and the other 14.6 kg (17.9%) over 6 months. No significant side effects; all reported lower insulin needs on pramlintide.
- Limits — Case reports.
A child with Nizon-Isidor syndrome (Stewart et al., 2026)
- What was given — A case series of a rare MED12L disorder.
- What it found — In one child, caloric restriction and semaglutide-pramlintide combination therapy started at age 8 were effective in weight reduction.
- Limits — One case.
No controlled trial of pramlintide with semaglutide turned up in PubMed, Europe PMC or ClinicalTrials.gov, where the one registered trial was withdrawn (searched September 29, 2026).
Legal Status
Pramlintide: FDA approved. Prescribed by a doctor, made by a manufacturer.
Semaglutide: FDA approved. Prescribed by a doctor, made by a manufacturer.
References
- Wong G, Garner EM, Srivastava G. Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes. JCEM Case Rep. 2023;1(2):luad040. PMID: 37908483.
- Stewart R, Ezell KM, Bell DS, Corner B, McMinn A, Cogan JD, et al. Case Series of Nizon-Isidor Syndrome by Heterozygous Variants in MED12L With Further Evidence of Mitotic Instability in One Case With Diploid-Triploid Mosaicism. Am J Med Genet A. 2026;200(1):205-214. PMID: 40838347.
Checked 14 Oct 2026 | A literature lookup, not a recommendation to combine anything.